BR112022018793A2 - Uso de um composto de fórmula (i) ou (ii) para tratar ou previnir uma infecção por coronaviridae e condições relacionadas, composição farmacêutica e medicamento compreendendo os mesmos, uso de um mirna como um biomarcador de uma infecção por coronaviridae, e método para avaliar uma infecção por coronaviridae - Google Patents

Uso de um composto de fórmula (i) ou (ii) para tratar ou previnir uma infecção por coronaviridae e condições relacionadas, composição farmacêutica e medicamento compreendendo os mesmos, uso de um mirna como um biomarcador de uma infecção por coronaviridae, e método para avaliar uma infecção por coronaviridae

Info

Publication number
BR112022018793A2
BR112022018793A2 BR112022018793A BR112022018793A BR112022018793A2 BR 112022018793 A2 BR112022018793 A2 BR 112022018793A2 BR 112022018793 A BR112022018793 A BR 112022018793A BR 112022018793 A BR112022018793 A BR 112022018793A BR 112022018793 A2 BR112022018793 A2 BR 112022018793A2
Authority
BR
Brazil
Prior art keywords
infection
coronaviridae
coronaviridae infection
evaluating
mirna
Prior art date
Application number
BR112022018793A
Other languages
English (en)
Portuguese (pt)
Inventor
Tazi Jamal
Ehrlich Hartmut
Pouletty Philippe
Santo Julien
Scherrer Didier
Original Assignee
Abivax
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP20305299.8A external-priority patent/EP3881844A1/en
Priority claimed from EP20305327.7A external-priority patent/EP3884946A1/en
Application filed by Abivax filed Critical Abivax
Publication of BR112022018793A2 publication Critical patent/BR112022018793A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
BR112022018793A 2020-03-20 2021-03-19 Uso de um composto de fórmula (i) ou (ii) para tratar ou previnir uma infecção por coronaviridae e condições relacionadas, composição farmacêutica e medicamento compreendendo os mesmos, uso de um mirna como um biomarcador de uma infecção por coronaviridae, e método para avaliar uma infecção por coronaviridae BR112022018793A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP20305299.8A EP3881844A1 (en) 2020-03-20 2020-03-20 Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection
EP20305327.7A EP3884946A1 (en) 2020-03-25 2020-03-25 Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection
EP20305482 2020-05-12
EP20306483 2020-12-03
PCT/EP2021/057123 WO2021186053A1 (en) 2020-03-20 2021-03-19 Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection

Publications (1)

Publication Number Publication Date
BR112022018793A2 true BR112022018793A2 (pt) 2022-11-29

Family

ID=74884979

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022018793A BR112022018793A2 (pt) 2020-03-20 2021-03-19 Uso de um composto de fórmula (i) ou (ii) para tratar ou previnir uma infecção por coronaviridae e condições relacionadas, composição farmacêutica e medicamento compreendendo os mesmos, uso de um mirna como um biomarcador de uma infecção por coronaviridae, e método para avaliar uma infecção por coronaviridae

Country Status (11)

Country Link
US (1) US20230142547A1 (https=)
EP (1) EP4121053A1 (https=)
JP (1) JP2023521564A (https=)
KR (1) KR20220152292A (https=)
CN (1) CN115605205A (https=)
AU (1) AU2021238792A1 (https=)
BR (1) BR112022018793A2 (https=)
CA (1) CA3172179A1 (https=)
IL (1) IL296522A (https=)
MX (1) MX2022011596A (https=)
WO (1) WO2021186053A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023126951A1 (en) * 2022-01-03 2023-07-06 Yeda Research And Development Co. Ltd. Inhibitors of autophagy-related protein-protein interactions
CN118373771A (zh) * 2023-01-20 2024-07-23 江苏柯菲平医药股份有限公司 一种喹啉衍生化合物或其可药用的盐及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070225363A1 (en) 2003-11-21 2007-09-27 The University Of Newcastle Research Associates Ltd. Methods and Agents for Inhibiting Dynamin-Dependent Endocytosis
SI2440547T1 (sl) 2009-06-12 2023-05-31 Abivax Nove kemične molekule, ki zavirajo mehanizem spajanja za zdravljenje bolezni, ki so posledica napak pri spajanju
EP2757161A1 (en) 2013-01-17 2014-07-23 Splicos miRNA-124 as a biomarker of viral infection
EP2862928A1 (en) 2013-10-18 2015-04-22 Université de Strasbourg Dynamin 2 inhibitor for the treatment of centronuclear myopathies
EP3058940A1 (en) * 2015-02-23 2016-08-24 Abivax Quinoline derivatives for use in the treatment or prevention of viral infection
EP3059236A1 (en) * 2015-02-23 2016-08-24 Abivax A new quinoline derivative for use in the treatment and prevention of viral infections
EP3594206A1 (en) 2018-07-09 2020-01-15 Abivax Phenyl-n-quinoline derivatives for treating a rna virus infection
EP3858815A1 (en) * 2020-01-31 2021-08-04 Abivax Co-crystals and salts of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine
CA3164700A1 (en) * 2020-01-31 2021-08-05 Abivax Amorphous solid dispersion of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine
KR20210151949A (ko) * 2020-04-05 2021-12-14 화이자 인코포레이티드 Covid-19의 치료를 위한 화합물 및 방법

Also Published As

Publication number Publication date
JP2023521564A (ja) 2023-05-25
EP4121053A1 (en) 2023-01-25
AU2021238792A1 (en) 2022-10-13
WO2021186053A1 (en) 2021-09-23
CA3172179A1 (en) 2021-09-23
KR20220152292A (ko) 2022-11-15
MX2022011596A (es) 2022-10-18
CN115605205A (zh) 2023-01-13
US20230142547A1 (en) 2023-05-11
IL296522A (en) 2022-11-01

Similar Documents

Publication Publication Date Title
BR112022023013A2 (pt) Inibidores de mek para tratamento ou prevenção de infecções por coronavírus e/ou de tempestade de citocinas de covid-19
BR112021022778A2 (pt) Compostos e métodos para o tratamento de covid-19
BR112021022758A2 (pt) Compostos de 1-oxo-isoindolina-5-carboxamida substituídos, suas composições e métodos de tratamento com os mesmos
MX2023007853A (es) Compuesto heterociclico puenteado que contiene nitrogeno, metodo de preparacion y uso medico del mismo.
BR112023025358A2 (pt) Inibidores de protease como antivirais
BR112012006686B8 (pt) compostos de amida substituída, composições farmacêuticas contendo os ditos compostos, e uso dos mesmos para prevenir e/ou tratar doenças causadas pelo lpa
BR112018071408A2 (pt) “composto inibidor de rip2 quinase, composição farmacêutica, usos de um composto e de uma combinação, e, combinação
MX2023010491A (es) Composicion farmaceutica para el tratamiento o la prevencion de la miastenia gravis.
BR112012021659A2 (pt) composto, composição farmacêutica, método para tratar e/ou prevenir distúrbios e doenças.
ECSP19083621A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
BR112023019030A2 (pt) Derivados de fósforo como inibidores de sos1
BR112023001792A2 (pt) Combinações para o tratamento de câncer
BR112019003731A2 (pt) aplicação de pridopidina para tratamento de distonias
BR112022025933A2 (pt) Compostos de ligação ao cereblon, composições dos mesmos e métodos de tratamento com os mesmos
BR112022025117A2 (pt) 2-amino-3-fluoro-but-3-enamidas macrocíclicas como inibidores de mcl-1
MX2017012545A (es) Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
BR112023022496A2 (pt) Composto heterocíclico contendo nitrogênio, método de preparação do mesmo, e aplicação do mesmo em medicamentos
MX2022013081A (es) Compuestos para el tratamiento de sars.
MX2023006504A (es) Compuesto de hidroxamato, metodo de preparacion del mismo y aplicacion del mismo.
BR112018006545A2 (pt) ?composto, composição farmacêutica, combinação, uso de um composto, e, método para tratamento de uma doença ou condição?
BR112022000251A2 (pt) Derivados macrocíclicos de espirociclo como inibidores de mcl-1
MX2022009176A (es) Metodo y composiciones para el tratamiento de infeccion por coronavirus.
BR112021025732A2 (pt) Inibidores macrocíclicos de mcl-1
BR112022018793A2 (pt) Uso de um composto de fórmula (i) ou (ii) para tratar ou previnir uma infecção por coronaviridae e condições relacionadas, composição farmacêutica e medicamento compreendendo os mesmos, uso de um mirna como um biomarcador de uma infecção por coronaviridae, e método para avaliar uma infecção por coronaviridae
BR112022001390A2 (pt) Inibidores de enzima

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.